Development of a reversed-phase ion-pairing liquid chromatographic assay of daunorubicin for pharmacopoeial use

Determination of Daunomycin in Human Plasma and Urine by Using an Interference-free Analysis of Excitation-Emission Matrix Fluorescence Data with Second-Order Calibration

Daunorubicin (DNR) is a significant antineoplastic antibiotic, which is usually applied to a chemotherapy of acute lymphatic and myelogenous leukaemia. Unfortunately, cardiotoxicity research in animals has indicated that DNR is cardiotoxic. Therefore, it is important to quantify DNR in biological fluids. A new algorithm, the alternating fitting residue (AFR) method, and the traditional parallel factor analysis (PARAFAC) have been utilized to directly determine DNR in human plasma and urine. These methodologies fully exploit the second-order advantage of the employed three-way fluorescence data, allowing the analyte concentrations to be quantified even in the presence of unknown fluorescent interferents. Furthermore, in contrast to PARAFAC, more satisfactory results were gained with AFR.

Liquid chromatographic methods validation for pharmaceutical products

The current status of validation in LC methods for the analysis of pharmaceuticals has been reviewed with special reference to compatibility testing methods. Validation data were provided in terms of method linearity, accuracy, precision, system suitability, specificity, use of alternate methods, injection order, application of peak height or area measurements and of internal or external standards.